MRTX1133 Suppresses ERK Signaling but Elicits Context-Dependent Antiproliferative Responses in KRAS (G12C) Cancer Cells
{{output}}
KRAS is a high-value therapeutic target for the treatment of cancer. Two covalent inhibitors, sotorasib and adagrasib, which target a specific codon 12 mutation (G12C), had received accelerated approvals for clinical use. Studies of these inhibitors ushered in... ...
